Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 9 papers. Top paper: “Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).”.
Peter C. Enzinger, Yoon-Koo Kang, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee +11 more
Xiaomei Zhuang, Cuiping Yang, Zheng Li, Shan Xiong, Zhiwei Zhang +4 more
Zishu Wang, Huan Zhou, Hongming Pan, Weidong Han, Yanhong Deng +13 more
Fang Jin, Liang Ma, Yongfeng Yang, Baogui Zhang, Dan Cao +6 more
Hope Kean, Evelina Fedorenko, Zeynep M. Saygin, Jin Li
Hope Kean, Evelina Fedorenko, Zeynep M. Saygin, Jin Li
Elana Schettini, Jin Li, Zeynep M. Saygin, Kelly J. Hiersche
Jianing Fang, Jiani Li, Xi Chen, Jin Li, Rosamaria Pennisi +7 more
David E. Osher, Heather A. Hansen, Zeynep M. Saygin, Jin Li